Milataxel is an orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).This compound is unstable in powder form and other related salt forms are recommended.
GNF179 Metabolite, the derivative of GNF179—an optimized 8,8-dimethyl IP analog—demonstrates significant potency (4.8 nM against the multidrug-resistant W2 strain) alongside in vitro metabolic stability and in vivo oral bioavailability.
Polymyxin B1, a potent antimicrobial lipopeptide derived from Bacillus polymyxa, has potential for treating multidrug-resistant Gram-negative bacterial infections.
SPR206 is a polymyxin analogue and an important class of antibiotic for the treatment of bacterial infections due to multidrug resistant Gram-negative pathogen.
BWC0977 是一种有效的拓扑异构酶抑制剂,可通过同时靶向 DNA gyrase 和 topoisomerase IV 干扰细菌 DNA 复制。BWC0977 对多重耐药革兰氏阴性菌的最低抑菌浓度(MIC90)范围为 0.03–2 µg/mL。因此,BWC0977 被用于抗菌药理学研究,以研究革兰氏阴性菌模型系统中的双重拓扑异构酶抑制机制及耐药性特征。